Kandefer-Szerszeń M, Legieć W, Dmoszyńska A, Rzeski W
Department of Virology and Immunology, Maria Curie-Skłodowska University, Lublin, Poland.
Arch Immunol Ther Exp (Warsz). 1997;45(5-6):443-8.
We measured the soluble IL-2 receptor alpha (sIL-2R alpha) in sera and in bone marrow of 20 patients with minimal residual hematological malignances, 6 of them with multiple myeloma (MM), 8 with Hodgkin's disease (HD) and 6 with non-Hodgkin's lymphoma (NHL), low grade. Compared to 10 normal individuals, HD and NHL group of patients had in sera significantly increased levels of sIL-2R alpha (252.8 +/- 42.9 versus 1437.2 +/- 1639 and 761.8 +/- 431 U/ml, respectively). After low-dose IL-2 given subcutaneously once daily at a dose of 1.8 x 10(6) U/patient for 3 weeks, additional significant increase in levels of IL-2R alpha was observed in sera and in bone marrow of patients with NHL (761.8 +/- 431 versus 2633 +/- 788 U/ml and 785 +/- 448 versus 2475 +/- 431 U/ml, respectively). The increase of sIL-2R alpha level after IL-2 therapy was also seen in sera and in bone marrow of HD and MM group; however, because of high standard deviation this increase was not statistically significant. We conclude that 1) in comparison to healthy subjects the levels of sIL-2R alpha remained elevated in HD and NHL patients, even at the stage of minimal residual disease (MRD) after intensive chemotherapy or radiotherapy, 2) the levels of sIL-2R alpha which appeared in sera and bone marrow of patients after IL-2 therapy seemed to be dependent on the type of hematological disorders.
我们检测了20例血液系统微小残留恶性肿瘤患者血清和骨髓中的可溶性白细胞介素-2受体α（sIL-2Rα），其中6例为多发性骨髓瘤（MM），8例为霍奇金病（HD），6例为低度非霍奇金淋巴瘤（NHL）。与10名正常个体相比，HD组和NHL组患者血清中sIL-2Rα水平显著升高（分别为252.8±42.9与1437.2±1639以及761.8±431 U/ml）。在以1.8×10⁶ U/患者的剂量皮下每日注射低剂量白细胞介素-2，持续3周后，NHL患者血清和骨髓中IL-2Rα水平进一步显著升高（分别为761.8±431与2633±788 U/ml以及785±448与2475±431 U/ml）。HD组和MM组患者血清和骨髓中也可见白细胞介素-2治疗后sIL-2Rα水平升高；然而，由于标准差较大，这种升高无统计学意义。我们得出结论：1）与健康受试者相比，HD和NHL患者即使在强化化疗或放疗后的微小残留病（MRD）阶段，sIL-2Rα水平仍保持升高；2）白细胞介素-2治疗后患者血清和骨髓中出现的sIL-2Rα水平似乎取决于血液系统疾病的类型。
